Canadian Stem Cell Approval Could Be the First of Many
By Catherine Shaffer
Monday, May 21, 2012
Osiris Therapeutics Inc. won a double victory today with the first ever marketing approval for a manufactured stem cell product and the first therapy for graft-vs.-host disease (GvHD). Health Canada issued marketing authorization for Osiris's stem cell therapy Prochymal (remestemcel-L) for GvHD in children.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.